Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cigna GroupCI · Entity 550 | Special Advisor | August 12, 2024 | August 14, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cigna Group
Report date August 12, 2024 · Filed August 14, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $.01 Par ValueSEC Table I · non-derivative | Direct | 32,833 |
Ending reported balance
After 2024-08-12 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2024-08-12 · Exercise / conversion · Acquired 7,200 · Balance 39,652 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 9, 2024. Row 2 · 2024-08-12 · Sale · Disposed 1,785 · Balance 37,867 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 9, 2024. Row 3 · 2024-08-12 · Sale · Disposed 5,034 · Balance 32,833 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 9, 2024. F2: Represents the weighted average price of the shares sold. The prices actually received ranged from $329.045 to $329.769 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $149.14 · Expires 2027-02-28 | Direct | 2,506 |
Reported balance
After 2024-08-12 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-08-12 · Exercise / conversion · Disposed 7,200 · Balance 2,506 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 9, 2024. F4: This option was granted on February 28, 2017. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. |
| Common Stock, $.01 Par ValueSEC Table I · non-derivative | IndirectBy 401(k) | 8,195.1041 |
Reported balance
Holding disclosure · report date 2024-08-12 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 8,195.1041 F3: Represents shares acquired through ongoing participation in The Cigna Group's 401(k) Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 9, 2024.
F2: Represents the weighted average price of the shares sold. The prices actually received ranged from $329.045 to $329.769 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.
F3: Represents shares acquired through ongoing participation in The Cigna Group's 401(k) Plan.
F4: This option was granted on February 28, 2017. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Cigna Holding Co
Report date December 20, 2018 · Filed December 26, 2018
Section 16 reporting ended · disclosed 2018-12-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $.25 Par ValueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 1
1 source rowRow 1 · 2018-12-20 · Disposition to issuer · Disposed 21,046 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. |
| Common Stock, $.25 Par ValueSEC Table I · non-derivative | IndirectBy 401(k) | 0 |
Reported balance
After 2018-12-20 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2018-12-20 · Disposition to issuer · Disposed 7,483.0845 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F8: Represents shares acquired through ongoing participation in Cigna's 401(k) Plan and disposed of in connection with the Merger. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $120.90 · Expires 2025-02-25 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-12-20 · Disposition to issuer · Disposed 7,300 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F3: This option was fully vested and exercisable at the time of the Merger. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $139.22 · Expires 2026-03-01 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-12-20 · Disposition to issuer · Disposed 8,509 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F5: Two-thirds of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $139.22 per share, with the remaining one-third of the option vesting on March 1, 2019. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $149.14 · Expires 2027-02-28 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-12-20 · Disposition to issuer · Disposed 9,706 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F6: One-third of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $149.135 per share, with the remaining two-thirds of the option vesting in two equal installments on February 28, 2019 and February 28, 2020. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $197.35 · Expires 2028-02-28 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-12-20 · Disposition to issuer · Disposed 8,142 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F7: This option, which would have vested in three equal installments beginning on February 28, 2019, was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $197.35 per share on the same vesting terms. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote)
F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.
F3: This option was fully vested and exercisable at the time of the Merger.
F4: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option.
F5: Two-thirds of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $139.22 per share, with the remaining one-third of the option vesting on March 1, 2019.
F6: One-third of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $149.135 per share, with the remaining two-thirds of the option vesting in two equal installments on February 28, 2019 and February 28, 2020.
F7: This option, which would have vested in three equal installments beginning on February 28, 2019, was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $197.35 per share on the same vesting terms.
F8: Represents shares acquired through ongoing participation in Cigna's 401(k) Plan and disposed of in connection with the Merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 12, 2024 Filed Aug 14, 2024 20:30 UTC | Cigna Group CI · Entity 550 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 7,200 | $0.00 Strike: $149.14 | $0.00 |
DisclosureSEC source: 0001225208-24-008010 · doc4.xml · derivative · entry 5 Triplett Michael W · CIK 0001698840 · Special Advisor 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,506 Underlying: Common Stock, $.01 Par Value · 7,200 shares Expires 2027-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 9, 2024. F4 · derivative.exercise_date: This option was granted on February 28, 2017. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 20:30 UTC | Cigna Group CI · Entity 550 | SaleCommon Stock, $.01 Par Value | 5,034 | $329.58 | $1,659,087.60 |
DisclosureSEC source: 0001225208-24-008010 · doc4.xml · nonDerivative · entry 3 Triplett Michael W · CIK 0001698840 · Special Advisor 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,833 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 9, 2024. F2 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $329.045 to $329.769 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 20:30 UTC | Cigna Group CI · Entity 550 | SaleCommon Stock, $.01 Par Value | 1,785 | $330.96 | $590,763.60 |
DisclosureSEC source: 0001225208-24-008010 · doc4.xml · nonDerivative · entry 2 Triplett Michael W · CIK 0001698840 · Special Advisor 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,867 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 9, 2024. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 20:30 UTC | Cigna Group CI · Entity 550 | Exercise / conversionCommon Stock, $.01 Par Value | 7,200 | $149.14 | $1,073,772.00 |
DisclosureSEC source: 0001225208-24-008010 · doc4.xml · nonDerivative · entry 1 Triplett Michael W · CIK 0001698840 · Special Advisor 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,652 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 9, 2024. Read SEC document |
| March 04, 2024 Filed Mar 5, 2024 22:43 UTC | Cigna Group CI · Entity 550 | SaleCommon Stock, $.01 Par Value | 1,953 | $332.62 | $649,606.86 |
DisclosureSEC source: 0001225208-24-003705 · doc4.xml · nonDerivative · entry 4 Triplett Michael W · CIK 0001698840 · Special Advisor 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,452 F4 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 16, 2023. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 22:43 UTC | Cigna Group CI · Entity 550 | Tax withholdingCommon Stock, $.01 Par Value | 2,492 | $333.36 | $830,733.12 |
DisclosureSEC source: 0001225208-24-003705 · doc4.xml · nonDerivative · entry 3 Triplett Michael W · CIK 0001698840 · Special Advisor 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,405 F3 · shares: Represents shares withheld to satisfy tax obligations upon settlement of strategic performance shares. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 22:43 UTC | Cigna Group CI · Entity 550 | Tax withholdingCommon Stock, $.01 Par Value | 749 | $333.36 | $249,686.64 |
DisclosureSEC source: 0001225208-24-003705 · doc4.xml · nonDerivative · entry 2 Triplett Michael W · CIK 0001698840 · Special Advisor 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,897 F2 · shares: Represents shares withheld to satisfy tax obligations upon vesting of restricted shares. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 22:43 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 5,702 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-003705 · doc4.xml · nonDerivative · entry 1 Triplett Michael W · CIK 0001698840 · Special Advisor 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,646 F1 · shares: The reported securities are shares of common stock received pursuant to the settlement of strategic performance shares for the 2021-2023 three-year performance period. The number of shares of common stock received was based upon actual performance against pre-established Company performance goals. Read SEC document |
| February 28, 2024 Filed Mar 2, 2024 00:44 UTC | Cigna Group CI · Entity 550 | GrantEmployee Stock Option (Right to Buy) · Derivative | 6,226 | $0.00 Strike: $336.48 | $0.00 |
DisclosureSEC source: 0001225208-24-003419 · doc4.xml · derivative · entry 3 Triplett Michael W · CIK 0001698840 · Special Advisor 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,226 Underlying: Common Stock, $.01 Par Value · 6,226 shares Expires 2034-02-28 F3 · derivative.exercise_date: This option vests in three equal annual installments beginning March 1, 2025. Read SEC document |
| February 28, 2024 Filed Mar 2, 2024 00:44 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 1,709 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-003419 · doc4.xml · nonDerivative · entry 1 Triplett Michael W · CIK 0001698840 · Special Advisor 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,944 F1 · shares: These restricted shares vest in three equal annual installments beginning March 1, 2025. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 23:23 UTC | Cigna Group CI · Entity 550 | SaleCommon Stock, $.01 Par Value | 1,731 | $271.67 | $470,260.77 |
DisclosureSEC source: 0001225208-23-003874 · doc4.xml · nonDerivative · entry 1 Triplett Michael W · CIK 0001698840 · President, U.S. Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,235 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2023. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 22:12 UTC | Cigna Group CI · Entity 550 | Tax withholdingCommon Stock, $.01 Par Value | 805 | $289.44 | $232,999.20 |
DisclosureSEC source: 0001225208-23-003387 · doc4.xml · nonDerivative · entry 1 Triplett Michael W · CIK 0001698840 · President, U.S. Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,966 F1 · kind: Represents shares withheld to satisfy tax obligations upon vesting of restricted shares. Read SEC document |
| February 24, 2023 Filed Feb 28, 2023 23:02 UTC | Cigna Group CI · Entity 550 | Tax withholdingCommon Stock, $.01 Par Value | 2,172 | $294.27 | $639,154.44 |
DisclosureSEC source: 0001225208-23-002999 · doc4.xml · nonDerivative · entry 3 Triplett Michael W · CIK 0001698840 · President, U.S. Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,771 F3 · shares: Represents shares withheld to satisfy tax obligations upon settlement of strategic performance shares. Read SEC document |
| February 24, 2023 Filed Feb 28, 2023 23:02 UTC | Cigna Group CI · Entity 550 | Tax withholdingCommon Stock, $.01 Par Value | 280 | $294.27 | $82,395.60 |
DisclosureSEC source: 0001225208-23-002999 · doc4.xml · nonDerivative · entry 2 Triplett Michael W · CIK 0001698840 · President, U.S. Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,943 F2 · shares: Represents shares withheld to satisfy tax obligations upon vesting of restricted shares. Read SEC document |
| February 24, 2023 Filed Feb 28, 2023 23:02 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 5,633 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002999 · doc4.xml · nonDerivative · entry 1 Triplett Michael W · CIK 0001698840 · President, U.S. Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,223 F1 · shares: The reported securities are shares of common stock received pursuant to the settlement of strategic performance shares for the 2020-2022 three-year performance period. The number of shares of common stock received was based upon actual performance against pre-established Company performance goals. Read SEC document |
| February 22, 2023 Filed Feb 25, 2023 02:13 UTC | Cigna Group CI · Entity 550 | GrantEmployee Stock Option (Right to Buy) · Derivative | 7,574 | $0.00 Strike: $294.61 | $0.00 |
DisclosureSEC source: 0001225208-23-002829 · doc4.xml · derivative · entry 3 Triplett Michael W · CIK 0001698840 · President, U.S. Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,574 Underlying: Common Stock, $.01 Par Value · 7,574 shares Expires 2033-02-22 F3 · derivative.exercise_date: This option vests in three equal annual installments beginning March 1, 2024. Read SEC document |
| February 22, 2023 Filed Feb 25, 2023 02:13 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 2,050 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-002829 · doc4.xml · nonDerivative · entry 1 Triplett Michael W · CIK 0001698840 · President, U.S. Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,590 F1 · shares: These restricted shares vest in three equal annual installments beginning March 1, 2024. Read SEC document |
| September 13, 2022 Filed Sep 14, 2022 21:32 UTC | Cigna Group CI · Entity 550 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 2,449 | $0.00 Strike: $139.22 | $0.00 |
DisclosureSEC source: 0001225208-22-010321 · doc4.xml · derivative · entry 6 Triplett Michael W · CIK 0001698840 · President, U.S. Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.01 Par Value · 2,449 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 12, 2022. F3 · derivative.exercise_date: This option was granted on March 1, 2016. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document |
| September 13, 2022 Filed Sep 14, 2022 21:32 UTC | Cigna Group CI · Entity 550 | Exercise / conversionCommon Stock, $.01 Par Value | 2,449 | $139.22 | $340,949.78 |
DisclosureSEC source: 0001225208-22-010321 · doc4.xml · nonDerivative · entry 3 Triplett Michael W · CIK 0001698840 · President, U.S. Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,540 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 12, 2022. Read SEC document |
| September 12, 2022 Filed Sep 14, 2022 21:32 UTC | Cigna Group CI · Entity 550 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 6,060 | $0.00 Strike: $139.22 | $0.00 |
DisclosureSEC source: 0001225208-22-010321 · doc4.xml · derivative · entry 5 Triplett Michael W · CIK 0001698840 · President, U.S. Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,449 Underlying: Common Stock, $.01 Par Value · 6,060 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 12, 2022. F3 · derivative.exercise_date: This option was granted on March 1, 2016. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document |
| September 12, 2022 Filed Sep 14, 2022 21:32 UTC | Cigna Group CI · Entity 550 | SaleCommon Stock, $.01 Par Value | 8,260 | $292.76 | $2,418,197.60 |
DisclosureSEC source: 0001225208-22-010321 · doc4.xml · nonDerivative · entry 2 Triplett Michael W · CIK 0001698840 · President, U.S. Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,091 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 12, 2022. Read SEC document |
| September 12, 2022 Filed Sep 14, 2022 21:32 UTC | Cigna Group CI · Entity 550 | Exercise / conversionCommon Stock, $.01 Par Value | 6,060 | $139.22 | $843,673.20 |
DisclosureSEC source: 0001225208-22-010321 · doc4.xml · nonDerivative · entry 1 Triplett Michael W · CIK 0001698840 · President, U.S. Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,351 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 12, 2022. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 22:29 UTC | Cigna Group CI · Entity 550 | Tax withholdingCommon Stock, $.01 Par Value | 405 | $236.48 | $95,774.40 |
DisclosureSEC source: 0001225208-22-004176 · doc4.xml · nonDerivative · entry 1 Triplett Michael W · CIK 0001698840 · President, U.S. Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,291 F1 · shares: Represents shares withheld to satisfy tax obligations upon vesting of restricted shares. Read SEC document |
| February 25, 2022 Filed Mar 2, 2022 01:19 UTC | Cigna Group CI · Entity 550 | Tax withholdingCommon Stock, $.01 Par Value | 805 | $229.64 | $184,860.20 |
DisclosureSEC source: 0001225208-22-003757 · doc4.xml · nonDerivative · entry 3 Triplett Michael W · CIK 0001698840 · President, U.S. Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,696 F3 · shares: Represents shares withheld to satisfy tax obligations upon settlement of strategic performance shares. Read SEC document |
| February 25, 2022 Filed Mar 2, 2022 01:19 UTC | Cigna Group CI · Entity 550 | Tax withholdingCommon Stock, $.01 Par Value | 539 | $229.64 | $123,775.96 |
DisclosureSEC source: 0001225208-22-003757 · doc4.xml · nonDerivative · entry 2 Triplett Michael W · CIK 0001698840 · President, U.S. Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,501 F2 · shares: Represents shares withheld to satisfy tax obligations upon vesting of restricted shares. Read SEC document |
| February 25, 2022 Filed Mar 2, 2022 01:19 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 2,641 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-003757 · doc4.xml · nonDerivative · entry 1 Triplett Michael W · CIK 0001698840 · President, U.S. Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,040 F1 · shares: The reported securities are shares of common stock received pursuant to the settlement of strategic performance shares for the 2019-2021 three-year performance period. The number of shares of common stock received was based upon actual performance against pre-established Company performance goals. Read SEC document |
| February 23, 2022 Filed Feb 26, 2022 01:49 UTC | Cigna Group CI · Entity 550 | GrantEmployee Stock Option (Right to Buy) · Derivative | 11,926 | $0.00 Strike: $227.02 | $0.00 |
DisclosureSEC source: 0001225208-22-003492 · doc4.xml · derivative · entry 3 Triplett Michael W · CIK 0001698840 · President, U.S. Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,926 Underlying: Common Stock, $.01 Par Value · 11,926 shares Expires 2032-02-23 F3 · derivative.exercise_date: This option vests in three equal annual installments beginning March 1, 2023. Read SEC document |
| February 23, 2022 Filed Feb 26, 2022 01:49 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 2,660 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-003492 · doc4.xml · nonDerivative · entry 1 Triplett Michael W · CIK 0001698840 · President, U.S. Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,399 F1 · shares: These restricted shares vest in three equal annual installments beginning March 1, 2023. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 21:28 UTC | Cigna Group CI · Entity 550 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 3,300 | $0.00 Strike: $120.90 | $0.00 |
DisclosureSEC source: 0001225208-21-009479 · doc4.xml · derivative · entry 5 Triplett Michael W · CIK 0001698840 · President, US Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.01 Par Value · 3,300 shares Expires 2025-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2021. F4 · derivative.exercise_date: This option was granted on February 25, 2015. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 21:28 UTC | Cigna Group CI · Entity 550 | GiftCommon Stock, $.01 Par Value | 175 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-009479 · doc4.xml · nonDerivative · entry 3 Triplett Michael W · CIK 0001698840 · President, US Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,739 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2021. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 21:28 UTC | Cigna Group CI · Entity 550 | SaleCommon Stock, $.01 Par Value | 3,075 | $240.70 | $740,159.88 |
DisclosureSEC source: 0001225208-21-009479 · doc4.xml · nonDerivative · entry 2 Triplett Michael W · CIK 0001698840 · President, US Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,914 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2021. F2 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $240.64 to $240.72 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 21:28 UTC | Cigna Group CI · Entity 550 | Exercise / conversionCommon Stock, $.01 Par Value | 3,300 | $120.90 | $398,953.50 |
DisclosureSEC source: 0001225208-21-009479 · doc4.xml · nonDerivative · entry 1 Triplett Michael W · CIK 0001698840 · President, US Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,989 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2021. Read SEC document |
| February 26, 2021 Filed Mar 3, 2021 01:28 UTC | Cigna Group CI · Entity 550 | Tax withholdingCommon Stock, $.01 Par Value | 798 | $210.31 | $167,827.38 |
DisclosureSEC source: 0001225208-21-004369 · doc4.xml · nonDerivative · entry 3 Triplett Michael W · CIK 0001698840 · President, US Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,689 F3 · shares: Represents shares withheld to satisfy tax obligations upon settlement of strategic performance shares. Read SEC document |
| February 26, 2021 Filed Mar 3, 2021 01:28 UTC | Cigna Group CI · Entity 550 | Tax withholdingCommon Stock, $.01 Par Value | 537 | $210.31 | $112,936.47 |
DisclosureSEC source: 0001225208-21-004369 · doc4.xml · nonDerivative · entry 2 Triplett Michael W · CIK 0001698840 · President, US Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,487 F2 · shares: Represents shares withheld to satisfy tax obligations upon vesting of restricted shares. Read SEC document |
| February 26, 2021 Filed Mar 3, 2021 01:28 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 2,648 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-004369 · doc4.xml · nonDerivative · entry 1 Triplett Michael W · CIK 0001698840 · President, US Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,024 F1 · shares: The reported securities are shares of common stock received pursuant to the settlement of strategic performance shares for the 2018-2020 three-year performance period. The number of shares of common stock received was based upon actual performance against pre-established Company performance goals. Read SEC document |
| February 24, 2021 Filed Feb 27, 2021 01:23 UTC | Cigna Group CI · Entity 550 | GrantEmployee Stock Option (Right to Buy) · Derivative | 12,826 | $0.00 Strike: $213.80 | $0.00 |
DisclosureSEC source: 0001225208-21-003978 · doc4.xml · derivative · entry 3 Triplett Michael W · CIK 0001698840 · President, US Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,826 Underlying: Common Stock, $.01 Par Value · 12,826 shares Expires 2031-02-24 F3 · derivative.exercise_date: This option vests in three equal annual installments beginning March 1, 2022. Read SEC document |
| February 24, 2021 Filed Feb 27, 2021 01:23 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 2,690 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003978 · doc4.xml · nonDerivative · entry 1 Triplett Michael W · CIK 0001698840 · President, US Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,376 F1 · shares: These restricted shares vest in three equal annual installments beginning March 1, 2022. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:15 UTC | Cigna Group CI · Entity 550 | GiftCommon Stock, $.01 Par Value | 200 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-014491 · doc4.xml · nonDerivative · entry 1 Triplett Michael W · CIK 0001698840 · President, US Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,686 Read SEC document |
| June 05, 2020 Filed Jun 9, 2020 00:25 UTC | Cigna Group CI · Entity 550 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 876 | $0.00 Strike: $120.90 | $0.00 |
DisclosureSEC source: 0001225208-20-008724 · doc4.xml · derivative · entry 6 Triplett Michael W · CIK 0001698840 · President, US Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,300 Underlying: Common Stock, $.01 Par Value · 876 shares Expires 2025-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 4, 2020. F3 · derivative.exercise_date: This option was granted on February 25, 2015. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document |
| June 05, 2020 Filed Jun 9, 2020 00:25 UTC | Cigna Group CI · Entity 550 | Exercise / conversionCommon Stock, $.01 Par Value | 876 | $120.90 | $105,904.02 |
DisclosureSEC source: 0001225208-20-008724 · doc4.xml · nonDerivative · entry 3 Triplett Michael W · CIK 0001698840 · President, US Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,886 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 4, 2020. Read SEC document |
| June 04, 2020 Filed Jun 9, 2020 00:25 UTC | Cigna Group CI · Entity 550 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 3,124 | $0.00 Strike: $120.90 | $0.00 |
DisclosureSEC source: 0001225208-20-008724 · doc4.xml · derivative · entry 5 Triplett Michael W · CIK 0001698840 · President, US Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,176 Underlying: Common Stock, $.01 Par Value · 3,124 shares Expires 2025-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 4, 2020. F3 · derivative.exercise_date: This option was granted on February 25, 2015. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document |
| June 04, 2020 Filed Jun 9, 2020 00:25 UTC | Cigna Group CI · Entity 550 | SaleCommon Stock, $.01 Par Value | 5,074 | $199.46 | $1,012,060.04 |
DisclosureSEC source: 0001225208-20-008724 · doc4.xml · nonDerivative · entry 2 Triplett Michael W · CIK 0001698840 · President, US Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,010 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 4, 2020. Read SEC document |
| June 04, 2020 Filed Jun 9, 2020 00:25 UTC | Cigna Group CI · Entity 550 | Exercise / conversionCommon Stock, $.01 Par Value | 3,124 | $120.90 | $377,675.98 |
DisclosureSEC source: 0001225208-20-008724 · doc4.xml · nonDerivative · entry 1 Triplett Michael W · CIK 0001698840 · President, US Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,084 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 4, 2020. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 01:46 UTC | Cigna Group CI · Entity 550 | Tax withholdingCommon Stock, $.01 Par Value | 1,033 | $179.41 | $185,330.53 |
DisclosureSEC source: 0001225208-20-003957 · doc4.xml · nonDerivative · entry 3 Triplett Michael W · CIK 0001698840 · President, US Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,960 F3 · shares: Represents shares withheld to satisfy tax obligations upon settlement of strategic performance shares. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 01:46 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 3,431 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003957 · doc4.xml · nonDerivative · entry 2 Triplett Michael W · CIK 0001698840 · President, US Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,993 F2 · shares: The reported securities are shares of common stock received pursuant to the settlement of strategic performance shares for the 2017-2019 three-year performance period. The number of shares of common stock received was based upon actual performance against pre-established Company performance goals. Read SEC document |
| February 27, 2020 Filed Mar 3, 2020 01:46 UTC | Cigna Group CI · Entity 550 | Tax withholdingCommon Stock, $.01 Par Value | 266 | $185.76 | $49,412.16 |
DisclosureSEC source: 0001225208-20-003957 · doc4.xml · nonDerivative · entry 1 Triplett Michael W · CIK 0001698840 · President, US Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,562 F1 · shares: Represents shares withheld to satisfy tax obligations upon vesting of restricted shares. Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 02:27 UTC | Cigna Group CI · Entity 550 | GrantEmployee Stock Option (Right to Buy) · Derivative | 10,008 | $0.00 Strike: $192.02 | $0.00 |
DisclosureSEC source: 0001225208-20-003814 · doc4.xml · derivative · entry 3 Triplett Michael W · CIK 0001698840 · President, US Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,008 Underlying: Common Stock, $.01 Par Value · 10,008 shares Expires 2030-02-26 F3 · derivative.exercise_date: This option vests in three equal annual installments beginning February 26, 2021. Read SEC document |
| February 26, 2020 Filed Feb 29, 2020 02:27 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 2,735 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003814 · doc4.xml · nonDerivative · entry 1 Triplett Michael W · CIK 0001698840 · President, US Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,828 F1 · shares: These restricted shares vests in three equal annual installments beginning February 26, 2021. Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 22:14 UTC | Cigna Group CI · Entity 550 | GiftCommon Stock, $.01 Par Value | 225 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-015301 · doc4.xml · nonDerivative · entry 1 Triplett Michael W · CIK 0001698840 · President, US Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,093 Read SEC document |
| March 01, 2019 Filed Mar 6, 2019 02:24 UTC | Cigna Group CI · Entity 550 | Tax withholdingCommon Stock, $.01 Par Value | 794 | $177.85 | $141,212.90 |
DisclosureSEC source: 0001225208-19-004748 · doc4.xml · nonDerivative · entry 2 Triplett Michael W · CIK 0001698840 · President, US Markets 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,318 F2 · shares: Represents shares withheld to satisfy tax obligations upon vesting. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.